San Diego, CA — Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced positive data from a Phase 1b study of the company’s lead product candidate, OTO-104, in patients with Ménière’s disease. Ik heb dit forum de voorbije weken al vrij grondig doorgelezen. Although the search was comprehensive, there was no literature eligible for KQ1 and KQ3, thereby identifying some significant gaps in the literature. There are options for you but you need to act quick. It has been hypothesized that the upregulation of NMDA receptors induced by cochlear excitotoxicity is responsible for aberrant excitation of auditory nerve fibers, which is perceived as tinnitus. The ATA – American Tinnitus Association estimates that 50 million Americans suffer from the condition. The factor structure, internal consistency, was evaluated using Cronbach’s alpha coefficient and item correlations were used to confirm reliability.
There are currently no drugs with proven efficacy for acute inner ear tinnitus or acute inner ear hearing loss. While it does not seem unlikely that AM-101 could also work in case of tinnitus provoked by other triggers of excitotoxicity, we do not know whether this holds true at this point. The next step in tinnitus treatment is usually sound therapy. Tinnitus may be short and transitory; however, it may also become permanent and seriously impact the ability to sleep, relax, or to concentrate, or lead to tiredness, irritation, nervousness, despair, frustration, or depression. About AM-101 AM-101 is a small molecule that selectively blocks NMDA receptors in the cochlea. Yet, the English version reports that for the three factors, there is a low internal consistency and low correlation among the different items. 5 million people in the UK (compared to today’s 10 million) will be affected by hearing loss as the population continues to get older.